Acrivon Therapeutics, Inc. (ACRV)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-11-16. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 59/100 (HIGH), 13.6 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 10.7% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Evidence and freshness
Record counts and statuses were computed on 2026-11-21. A source date shows only when we store one; otherwise it says “not recorded”. Spot an error? Report a data error.
| PDUFA / FDA dates | 0 | No records No upcoming FDA decision date found in the company's SEC filings |
SEC 8-K filing |
| Clinical trials | 3 | Current Updated within the last 14 days |
ClinicalTrials.gov Registry queried: Nov 16, 2026 · ingested Nov 16, 2026 |
| Insider activity | 1 | Current Updated within the last 10 days |
SEC EDGAR Form 4 Window ends: Nov 21, 2026 · ingested Nov 21, 2026 |
| Dilution risk | 1 | Derived Derived score calculated from SEC data, not a raw record |
DilutionWatch score (derived from SEC filings) source date not recorded · ingested Nov 20, 2026 |
| Short interest | 1 | Current Updated within the last 21 days |
FINRA short interest source date not recorded · ingested Nov 20, 2026 |
| Publications | 5 | Current Updated within the last 30 days |
PubMed source date not recorded · ingested Nov 20, 2026 |
How the signal grade is calculated
The score (0–100) is a weighted average of the source-backed signals we hold for a company: FDA decision date 35%, clinical trials 25%, insider buying 15%, dilution risk 8%, signal convergence 7%, short interest 3%, and 0.5–2% each for smaller signals. A signal we have no record for drops out and the others share its weight. Grades: A ≥ 80, B ≥ 65, C ≥ 50, D ≥ 35, F below 35.
What drives this company's 32.5/100 (grade F):
- Clinical trials: signal score 0.42, weight used 49%, 20.2 points
- Dilution risk: signal score 0.59, weight used 16%, 9.2 points
- Short interest: signal score 0.50, weight used 6%, 2.9 points
- Publications: signal score 0.25, weight used 1%, 0.2 points
- Insider buying (Form 4): signal score 0.00, weight used 29%, 0.0 points
Freshness: PDUFA dates that have passed score 0; clinical-trial records older than 90 days are ignored; dilution scores older than 7 days are withdrawn; scores are recalculated daily. Derived signals: the overall score and grade, the dilution-risk score (DilutionWatch, calculated from SEC filings) and signal convergence. The grade is not a forecast of FDA approval, a trial result or a stock move, and not investment advice.
Recent News & SEC Filings
- Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB
- Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium
- Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027
- What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock
- Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?
- Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
- Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma. — Clin Cancer Res 2025 Oct 1 PMID 40711475
- Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance. — Cell Rep 2022 Aug 9 PMID 35947955
- Extracellular Hsp90 and protection of neuronal cells through Nrf2. — Biochem Soc Trans 2021 Nov 1 PMID 34415306
- Publisher Correction: Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs. — Nat Biomed Eng 2018 Sep PMID 31015683
- Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs. — Nat Biomed Eng 2018 Nov PMID 30918745
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Acrivon Therapeutics, Inc..
Full ACRV Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.